Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	7.42	13.19	54.64	18.96	3.63
Short-Term Investments	0	0	0	0	7.63
Cash & Cash Equivalents	7.42	13.19	54.64	18.96	11.26
Cash Growth	-43.76%	-75.86%	188.21%	68.42%	5.54%
Receivables	0.14	1.92	4.8	4.39	5.24
Inventory	0	0.02	0.04	0	0.02
Other Current Assets	0.84	1.29	2.37	2.66	1.2
Total Current Assets	8.4	16.42	61.85	26.01	17.72
Property, Plant & Equipment	1.97	2.41	2.7	1.61	1.45
Long-Term Investments	0.13	0.13	0.23	0.15	0.1
Goodwill and Intangibles	10.5	14.41	14.45	15.99	16.84
Other Long-Term Assets	0	0	1	0	0
Total Long-Term Assets	12.6	16.95	18.37	17.75	18.38
Total Assets	20.99	33.37	80.21	43.76	36.11
Accounts Payable	0.45	2.88	3.37	2.57	2.08
Deferred Revenue	0	0.09	0	0	0
Current Debt	0	5.93	0	0	0
Other Current Liabilities	4.17	13.21	16.52	12.65	10.08
Total Current Liabilities	4.62	22.11	19.89	15.23	12.16
Long-Term Debt	0	13.49	32.83	0	0
Other Long-Term Liabilities	9.07	8.68	4.41	3.97	2.95
Total Long-Term Liabilities	9.07	22.17	37.24	3.97	2.95
Total Liabilities	13.69	44.28	57.13	19.19	15.11
Total Debt	0	19.42	32.83	0	0
Debt Growth	-	-40.86%	-	-	-
Retained Earnings	-335.13	-303.82	-262.17	-177.79	-114.29
Shareholders' Equity	7.3	-10.92	23.08	24.56	21
Net Cash / Debt	7.42	-6.23	21.8	18.96	11.26
Net Cash / Debt Growth	-	-	15.01%	68.42%	5.54%
Working Capital	3.78	-5.7	41.96	10.78	5.56
Book Value Per Share	9.11	-278.26	591.86	944.32	1370.93

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).